¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ¿¹Ãø(-2028³â) : COVID-19ÀÇ ¿µÇâ°ú ºÐ¼® - Á¦Ç°º°, ¼ºñ½ºº°, ¿ø·áº°, Áö¿ªº°
Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product ; Service, and Source, and Geography
¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ±Ô¸ð´Â 2021³â¿¡ 157¾ï 3,504¸¸ ´Þ·¯¸¦ ±â·ÏÇß½À´Ï´Ù. ½ÃÀåÀº 2021-2028³â°£ 8.5%ÀÇ CAGR·Î È®´ëµÇ°í, 2028³â¿¡´Â 278¾ï 6,850¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Á¦¾à ±â¾÷¿¡ ÀÇÇÑ ¾Æ¿ô¼Ò½Ì Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â °¡Àå Áß¿äÇÑ ¿äÀÎÀÇ Çϳª°¡ µÇ°í ÀÖ½À´Ï´Ù. »ý»ê´É·Â °úÀ× À§ÇèÀ» °æ°¨Çϱâ À§Çؼ Á¦Á¶ ¾Æ¿ô¼Ò½Ì ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷°ú ¼öŹÁ¦Á¶ ±â¾÷ÀÇ °è¾à °Ç¼ö Áõ°¡´Â ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀåÀÇ ½ÃÀå ±Ô¸ð È®´ë¸¦ ³ªÅ¸³»°í ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶(Biopharmaceutical Contract Manufacturing) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² Á¦Ç°º°, ¼ºñ½ºº°, ¿ø·áº°, Áö¿ªº° µ¿Çâ ¹× ½ÃÀå¿¡ Âü¿©ÇÏ´Â ±â¾÷ °³¿ä µîÀ» Á¦°øÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå - Áß¿äÇÑ Æ÷ÀÎÆ®
Á¦3Àå Á¶»ç ¹æ¹ý
Á¦4Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ - ½ÃÀå »óȲ
- °³¿ä
- PEST ºÐ¼®
- Àü¹®°¡ÀÇ °ßÇØ
Á¦5Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- ½ÃÀå ±âȸ
- ÇâÈÄ µ¿Çâ
- ¿µÇ⠺м®
Á¦6Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå - ¼¼°è ºÐ¼®
- ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ¸ÅÃâ ¿¹Ãø°ú ºÐ¼®
- ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå, Áö¿ªº° - ¿¹Ãø°ú ºÐ¼®
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×
Á¦7Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ºÐ¼® - Á¦Ç°º°
- °³¿ä
- ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ¸ÅÃâ Á¡À¯À², Á¦Ç°º°(2021³â ¹× 2028³â)
- »ý¹°Á¦Á¦
- ¹ÙÀÌ¿À½Ã¹Ð·¯
Á¦8Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå - ¼ºñ½ºº°
- °³¿ä
- ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå, ¼ºñ½ºº°, 2021³â ¹× 2028³â(%)
- ÇÁ·Î¼¼½º °³¹ß
- ¿ÏÁ¦(Fill and Finish) ÀÛ¾÷
- ºÐ¼®¡¤Ç°Áú °ü¸® ½ÃÇè
- Æ÷Àå
Á¦9Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå - ¿ø·áº°
- °³¿ä
- ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå, ¿ø·áº°, 2021³â ¹× 2028³â(%)
- Æ÷À¯·ù ±â¹Ý »ý¹°Á¦Á¦
- ¹Ì»ý¹°/ºñÆ÷À¯·ù ±â¹Ý »ý¹°Á¦Á¦
Á¦10Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå - Áö¿ª ºÐ¼®
- ºÏ¹Ì : ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå
- À¯·´ : ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå
- Áß³²¹Ì : ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå
Á¦11Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå¿¡ ´ëÇÑ COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ
- ºÏ¹Ì : COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ Æò°¡
- À¯·´ : COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ Æò°¡
- ¾Æ½Ã¾ÆÅÂÆò¾ç : COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ Æò°¡
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ Æò°¡
- Áß³²¹Ì : COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ Æò°¡
Á¦12Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå - ¾÷°è »óȲ
- °³¿ä
- ½ÃÀå Âü¿© ±â¾÷¿¡ ÀÇÇÑ ¼ºÀå Àü·«(%)
- À¯±âÀû °³¹ß
- ¹«±âÀû °³¹ß
Á¦13Àå ±â¾÷ °³¿ä
- Boehringer Ingelheim International GmbH
- THERMO FISHER SCIENTIFIC INC.
- General Electric Company
- MERCK KGAA
- Lonza
- Samsung Biologics
- AbbVie Inc.
- WUXI BIOLOGICS
- Ajinomoto Co. Inc.
- Inno Bio Ventures Sdn Bhd
Á¦14Àå ºÎ·Ï
KSM 22.03.21
The biopharmaceutical contract manufacturing market is projected to reach US$ 27,868.50 million by 2028 from US$ 15,735.04 million in 2021; it is expected to grow at a CAGR of 8.5% from 2021 to 2028. The rising outsourcing by pharmaceutical companies is one of the most key factors driving the growth of the market. A few years ago, the contract manufacturing industry was a niche service market offering additional manufacturing capacity or specific services to pharmaceutical companies. The rise of CMOs was fueled by the increasing number of drug manufacturing failures. In the past, pharmaceutical companies had undertaken manufacturing facilities to develop innovative drugs. However, to reduce the risk of overcapacities, the demand for manufacturing outsourcing has continuously risen. Recently, Revolo Biotherapeutics entered into a partnership with contract development and manufacturing organization (CDMO)-Northway Biotech-to manufacture Revolo's binding immuno-regulatory protein 1805. The partnership included services from cell line development to manufacturing protein with quality assurance and regulatory compliance support. Similarly, Gland Pharma has been manufacturing Remdesivir for four companies, including Mylan, since 2021. Also, the organization increased its manufacturing quotas due to high demand from the companies. In 2019, Samsung Biologics and GI Innovation signed a contract for immunochemotherapy. Under this agreement, Samsung Biologics was providing services ranging from f-cell lines development to production of Phase-I drug substances. The increasing number of contracts between biopharmaceutical companies and contract manufacturing companies shows an increasing market size for the biopharmaceutical contract manufacturing market.
The global biopharmaceutical contract management market is bifurcated on the basis of product, service, and source. Based on product, the market is segmented into biologics and biosimilar. The biologics segment would account for the largest market share during 2021-2028. Biologics are expected to see robust growth due to the various products under the segment, such as monoclonal antibodies, recombinant proteins, vaccines, and others. Biologics have an increasing demand with increasing research and developmental activities to develop new drug products for chronic indications. The COVID-19 pandemic is also expected to drive the growth of the biologics segment with the demand for vaccines for the virus rising. Also, monoclonal antibodies are needed for various chronic illnesses of metabolic, infectious, neurological, and other origins.
By service, the biopharmaceutical contract management market is segmented into process development, fill and finish operations, analytical and quality control studies, and packaging. The process development segment is expected to hold the largest share of the market during the forecast period due to highest investments in process development for production of any biopharmaceutical. The focus on pilot to commercial scale-up process development, cell line development, and other processes are expected to create growth opportunities for process development segment. The segment is further divided into downstream and upstream processing with downstream processing holding the larger share as downstream processing involves a larger amount of products being developed. The analytical and quality control studies segment is expected to have the largest growth rate.
By source, the biopharmaceutical contract management market is segmented into mammalian and microbial-based biologics/non-mammalian. The mammalian segment is expected to hold a larger share of the market as mammalian sources of cells are more commonly used in the industry and can develop a larger range of products compared to microbial-based biologics/non-mammalian sources.
The World Health Organization (WHO), Association of Clinical Research Organizations (ACRO), European Federation of Pharmaceuticals Industries Associations (EFPIA), and Pharmaceutical Research and Manufacturers of America (PhRMA) are among the primary and secondary sources referred to while preparing the report on the biopharmaceutical contract management market.
Reasons to Buy:
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the biopharmaceuticals contract manufacturing market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global biopharmaceuticals contract manufacturing market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table Of Contents
1. Introduction
- 1.1 Study Scope
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 Global Biopharmaceutical Contract Manufacturing Market - By Product
- 1.3.2 Global Biopharmaceutical Contract Manufacturing Market - By Service
- 1.3.3 Global Biopharmaceutical Contract Manufacturing Market - By Source
- 1.3.4 Global Biopharmaceutical Contract Manufacturing Market - By Geography
2. Biopharmaceutical Contract Manufacturing Market - Key Takeaways
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. Biopharmaceutical Contract Manufacturing - Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 North America - PEST Analysis
- 4.2.2 Europe - PEST Analysis
- 4.2.3 Asia Pacific - PEST Analysis
- 4.2.4 Middle East and Africa (MEA) - PEST Analysis
- 4.2.5 South and Central America - PEST Analysis
- 4.3 Expert Opinion
5. Biopharmaceuticals Contract Manufacturing Market - Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Rising Outsourcing by Pharmaceutical Companies
- 5.1.2 Increasing Demand for Biologics
- 5.2 Market Restraints
- 5.2.1 Growing Competition in Industry
- 5.3 Market Opportunities
- 5.4 Future Trends
- 5.4.1 Consolidation in Pharmaceutical CMO Industry
- 5.4.2 COVID-19 Pandemic
- 5.5 Impact Analysis
6. Biopharmaceutical Contract Manufacturing Market - Global Analysis
- 6.1 Global Biopharmaceutical Contract Manufacturing Market Revenue Forecast and Analysis
- 6.2 Global Biopharmaceutical Contract Manufacturing Market, By Geography - Forecast And Analysis
- 6.3 Market Positioning of Key Players
7. Biopharmaceuticals Contract Manufacturing Market Analysis - By Product
- 7.1 Overview
- 7.2 Biopharmaceuticals Contract Manufacturing Market Revenue Share, by Product (2021 and 2028)
- 7.3 Biologics
- 7.3.1 Overview
- 7.3.2 Biologics: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.2.1 Monoclonal Antibodies
- 7.3.2.1.1 Overview
- 7.3.2.1.2 Monoclonal Antibodies: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.2.2 Recombinant Proteins
- 7.3.2.2.1 Overview
- 7.3.2.2.2 Recombinant Proteins: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.2.3 Vaccines
- 7.3.2.3.1 Overview
- 7.3.2.3.2 Vaccines: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.2.4 Others
- 7.3.2.4.1 Overview
- 7.3.2.4.2 Others: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4 Biosimilar
- 7.4.1 Overview
- 7.4.2 Biosimilar: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
8. Biopharmaceuticals Contract Manufacturing Market - By Service
- 8.1 Overview
- 8.2 Biopharmaceuticals Contract Manufacturing Market, by Service, 2021 and 2028 (%)
- 8.3 Process Development
- 8.3.1 Overview
- 8.3.2 Process Development: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 8.3.2.1 Downstream Processing
- 8.3.2.1.1 Overview
- 8.3.2.1.2 Downstream Processing: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 8.3.2.2 Upstream Processing
- 8.3.2.2.1 Overview
- 8.3.2.2.2 Upstream Processing: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 8.4 Fill and Finish Operations
- 8.4.1 Overview
- 8.4.2 Fill and Finish Operations: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 8.5 Analytical and Quality Control Studies
- 8.5.1 Overview
- 8.5.2 Analytical and Quality Control Studies: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 8.6 Packaging
- 8.6.1 Overview
- 8.6.2 Packaging: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
9. Biopharmaceuticals Contract Manufacturing Market - By Source
- 9.1 Overview
- 9.2 Biopharmaceuticals Contract Manufacturing Market, by Source, 2021 and 2028 (%)
- 9.3 Mammalian-Based Biologics
- 9.3.1 Overview
- 9.3.2 Mammalian-Based Biologics: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 9.4 Microbial/Non-Mammalian-Based Biologics
- 9.4.1 Overview
- 9.4.2 Microbial/Non-Mammalian-Based Biologics: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
10. Biopharmaceutical Contract Manufacturing Market - Geographic Analysis
- 10.1 North America: Biopharmaceutical Contract Manufacturing Market
- 10.1.1 Overview
- 10.1.2 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.3 North America: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.1.3.1 North America: Biologics Market, 2019-2028 (USD Million)
- 10.1.4 North America: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.1.4.1 North America: Process Development Market, 2019-2028 (USD Million)
- 10.1.5 North America: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.1.6 North America: Biopharmaceutical Contract Manufacturing Market, by Country, 2021 & 2028 (%)
- 10.1.6.1 US: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.6.1.1 US: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.6.1.2 US: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.1.6.1.2.1 US: Biologics Market, 2019-2028 (USD Million)
- 10.1.6.1.3 US: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.1.6.1.3.1 US: Process Development Market, 2019-2028 (USD Million)
- 10.1.6.1.4 US: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.1.6.2 Canada: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.6.2.1 Canada: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.6.2.2 Canada: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.1.6.2.2.1 Canada: Biologics Market, 2019-2028 (USD Million)
- 10.1.6.2.3 Canada: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.1.6.2.3.1 Canada: Process Development Market, 2019-2028 (USD Million)
- 10.1.6.2.4 Canada: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.1.6.3 Mexico: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.6.3.1 Mexico: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.1.6.3.2 Mexico: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.1.6.3.2.1 Mexico: Biologics Market, 2019-2028 (USD Million)
- 10.1.6.3.3 Mexico: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.1.6.3.3.1 Mexico: Process Development Market, 2019-2028 (USD Million)
- 10.1.6.3.4 Mexico: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.2 Europe: Biopharmaceutical Contract Manufacturing Market
- 10.2.1 Overview
- 10.2.2 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.3 Europe: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.2.3.1 Europe: Biologics Market, 2019-2028 (USD Million)
- 10.2.4 Europe: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.2.4.1 Europe: Process Development Market, 2019-2028 (USD Million)
- 10.2.5 Europe: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.2.6 Europe: Biopharmaceutical Contract Manufacturing Market, by Country, 2021 & 2028 (%)
- 10.2.6.1 Germany: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.6.1.1 Germany: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.6.1.2 Germany: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.2.6.1.2.1 Germany: Biologics Market, 2019-2028 (USD Million)
- 10.2.6.1.3 Germany: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.2.6.1.3.1 Germany: Process Development Market, 2019-2028 (USD Million)
- 10.2.6.1.4 Germany: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.2.6.2 UK: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.6.2.1 UK: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.6.2.2 UK: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.2.6.2.2.1 UK: Biologics Market, 2019-2028 (USD Million)
- 10.2.6.2.3 UK: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.2.6.2.3.1 UK: Process Development Market, 2019-2028 (USD Million)
- 10.2.6.2.4 UK: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.2.6.3 France: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.6.3.1 France: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.6.3.2 France: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.2.6.3.2.1 France: Biologics Market, 2019-2028 (USD Million)
- 10.2.6.3.3 France: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.2.6.3.3.1 France: Process Development Market, 2019-2028 (USD Million)
- 10.2.6.3.4 France: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.2.6.4 Spain: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.6.4.1 Spain: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.6.4.2 Spain: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.2.6.4.2.1 Spain: Biologics Market, 2019-2028 (USD Million)
- 10.2.6.4.3 Spain: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.2.6.4.3.1 Spain: Process Development Market, 2019-2028 (USD Million)
- 10.2.6.4.4 Spain: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.2.6.5 Italy: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.6.5.1 Italy: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.6.5.2 Italy: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.2.6.5.2.1 Italy: Biologics Market, 2019-2028 (USD Million)
- 10.2.6.5.3 Italy: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.2.6.5.3.1 Italy: Process Development Market, 2019-2028 (USD Million)
- 10.2.6.5.4 Italy: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.2.6.6 Rest of Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.6.6.1 Rest of Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.2.6.6.2 Rest of Europe: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.2.6.6.2.1 Rest of Europe: Biologics Market, 2019-2028 (USD Million)
- 10.2.6.6.3 Rest of Europe: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.2.6.6.3.1 Rest of Europe: Process Development Market, 2019-2028 (USD Million)
- 10.2.6.6.4 Rest of Europe: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.3 Asia Pacific: Biopharmaceutical Contract Manufacturing Market
- 10.3.1 Overview
- 10.3.2 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.3 Asia Pacific: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.3.3.1 Asia Pacific: Biologics Market, 2019-2028 (USD Million)
- 10.3.4 Asia Pacific: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.3.4.1 Asia Pacific: Process Development Market, 2019-2028 (USD Million)
- 10.3.5 Asia Pacific: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.3.6 Asia Pacific: Biopharmaceutical Contract Manufacturing Market, by Country, 2021 & 2028 (%)
- 10.3.6.1 China: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.6.1.1 China: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.6.1.2 China: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.3.6.1.2.1 China: Biologics Market, 2019-2028 (USD Million)
- 10.3.6.1.3 China: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.3.6.1.3.1 China: Process Development Market, 2019-2028 (USD Million)
- 10.3.6.1.4 China: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.3.6.2 Japan: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.6.2.1 Japan: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.6.2.2 Japan: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.3.6.2.2.1 Japan: Biologics Market, 2019-2028 (USD Million)
- 10.3.6.2.3 Japan: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.3.6.2.3.1 Japan: Process Development Market, 2019-2028 (USD Million)
- 10.3.6.2.4 Japan: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.3.6.3 India: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.6.3.1 India: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.6.3.2 India: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.3.6.3.2.1 India: Biologics Market, 2019-2028 (USD Million)
- 10.3.6.3.3 India: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.3.6.3.3.1 India: Process Development Market, 2019-2028 (USD Million)
- 10.3.6.3.4 India: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.3.6.4 South Korea: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.6.4.1 South Korea: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.6.4.2 South Korea: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.3.6.4.2.1 South Korea: Biologics Market, 2019-2028 (USD Million)
- 10.3.6.4.3 South Korea: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.3.6.4.3.1 South Korea: Process Development Market, 2019-2028 (USD Million)
- 10.3.6.4.4 South Korea: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.3.6.5 Australia: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.6.5.1 Australia: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.6.5.2 Australia: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.3.6.5.2.1 Australia: Biologics Market, 2019-2028 (USD Million)
- 10.3.6.5.3 Australia: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.3.6.5.3.1 Australia: Process Development Market, 2019-2028 (USD Million)
- 10.3.6.5.4 Australia: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.3.6.6 Rest of Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.6.6.1 Rest of Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.3.6.6.2 Rest of Asia Pacific: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.3.6.6.2.1 Rest of Asia Pacific: Biologics Market, 2019-2028 (USD Million)
- 10.3.6.6.3 Rest of Asia Pacific: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.3.6.6.3.1 Rest of Asia Pacific: Process Development Market, 2019-2028 (USD Million)
- 10.3.6.6.4 Rest of Asia Pacific: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.4 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market
- 10.4.1 Overview
- 10.4.2 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.4.3 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.4.3.1 Middle East & Africa: Biologics Market, 2019-2028 (USD Million)
- 10.4.4 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.4.4.1 Middle East & Africa: Process Development Market, 2019-2028 (USD Million)
- 10.4.5 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.4.6 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Share by Country - 2021 & 2028, (%)
- 10.4.6.1 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.4.6.1.1 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.4.6.1.2 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.4.6.1.2.1 Saudi Arabia: Biologics Market, 2019-2028 (USD Million)
- 10.4.6.1.3 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.4.6.1.3.1 Saudi Arabia: Process Development Market, 2019-2028 (USD Million)
- 10.4.6.1.4 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.4.6.2 UAE: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.4.6.2.1 UAE: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.4.6.2.2 UAE: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.4.6.2.2.1 UAE: Biologics Market, 2019-2028 (USD Million)
- 10.4.6.2.3 UAE: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.4.6.2.3.1 UAE: Process Development Market, 2019-2028 (USD Million)
- 10.4.6.2.4 UAE: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.4.6.3 South Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 10.4.6.3.1 South Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.4.6.3.2 South Africa: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.4.6.3.2.1 South Africa: Biologics Market, 2019-2028 (USD Million)
- 10.4.6.3.3 South Africa: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.4.6.3.3.1 South Africa: Process Development Market, 2019-2028 (USD Million)
- 10.4.6.3.4 South Africa: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.4.6.4 Rest of Middle East and Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 10.4.6.4.1 Rest of Middle East and Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.4.6.4.2 Rest of Middle East and Africa: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.4.6.4.2.1 Rest of Middle East and Africa: Biologics Market, 2019-2028 (USD Million)
- 10.4.6.4.3 Rest of Middle East and Africa: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.4.6.4.3.1 Rest of Middle East and Africa: Process Development Market, 2019-2028 (USD Million)
- 10.4.6.4.4 Rest of Middle East and Africa: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.5 South and Central America: Biopharmaceutical Contract Manufacturing Market
- 10.5.1 Overview
- 10.5.2 South and Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (US$ Million)
- 10.5.3 South and Central America: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.5.3.1 South and Central America: Biologics Market, 2019-2028 (USD Million)
- 10.5.4 South and Central America: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.5.4.1 South and Central America: Process Development Market, 2019-2028 (USD Million)
- 10.5.5 South and Central America: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.5.6 South and Central America: Biopharmaceutical Contract Manufacturing Market, by Country, 2021 & 2028 (%)
- 10.5.6.1 Brazil: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.5.6.1.1 Brazil: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.5.6.1.2 Brazil: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.5.6.1.2.1 Brazil: Biologics Market, 2019-2028 (USD Million)
- 10.5.6.1.3 Brazil: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.5.6.1.3.1 Brazil: Process Development Market, 2019-2028 (USD Million)
- 10.5.6.1.4 Brazil: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.5.6.2 Argentina: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.5.6.2.1 Argentina: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.5.6.2.2 Argentina: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.5.6.2.2.1 Argentina: Biologics Market, 2019-2028 (USD Million)
- 10.5.6.2.3 Argentina: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.5.6.2.3.1 Argentina: Process Development Market, 2019-2028 (USD Million)
- 10.5.6.2.4 Argentina: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
- 10.5.6.3 Rest of South and Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.5.6.3.1 Rest of South and Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2028 (USD Million)
- 10.5.6.3.2 Rest of South and Central America: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
- 10.5.6.3.2.1 Rest of South and Central America: Biologics Market, 2019-2028 (USD Million)
- 10.5.6.3.3 Rest of South and Central America: Biopharmaceutical Contract Manufacturing Market, by Service, 2019-2028 (USD Million)
- 10.5.6.3.3.1 Rest of South and Central America: Process Development Market, 2019-2028 (USD Million)
- 10.5.6.3.4 Rest of South and Central America: Biopharmaceutical Contract Manufacturing Market, by Source, 2019-2028 (USD Million)
11. Impact of COVID-19 Pandemic on Biopharmaceutical Contract Manufacturing Market
- 11.1 North America: Impact Assessment of COVID-19 Pandemic
- 11.2 Europe: Impact Assessment of COVID-19 Pandemic
- 11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
- 11.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
- 11.5 South and Central America: Impact Assessment of COVID-19 Pandemic
12. Biopharmaceutical Contract Manufacturing Market - Industry Landscape
- 12.1 Overview
- 12.2 Growth Strategies Done by the Companies in the Market, (%)
- 12.3 Organic Developments
- 12.4 Inorganic Developments
13. Company Profiles
- 13.1 Boehringer Ingelheim International GmbH
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 THERMO FISHER SCIENTIFIC INC.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 General Electric Company
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 MERCK KGAA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 Lonza
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 Samsung Biologics
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 AbbVie Inc.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 WUXI BIOLOGICS
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 13.9 Ajinomoto Co. Inc.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
- 13.10 Inno Bio Ventures Sdn Bhd
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
- 14.1 About The Insight Partners
- 14.2 Glossary of Terms